Abbott Laboratories (ABT)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $187.95B
Last updated: Nov 17, 2026 at 11:05 AM ET
Abbott Laboratories (ABT) Earnings: Report Dates and Results
Abbott Laboratories (ABT) is expected to report earnings on Jan 20, 2027. In the quarter ended Sep 30, 2026, Abbott Laboratories reported EPS of $1.42, below the $1.43 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ABT has an expected report date of Jan 20, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 10.0% above the $1.50 reported for the quarter ended Dec 31, 2025.
ABT Earnings Call
The latest ABT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, ABT beat 29, missed 1 and matched 10. Revenue for the quarter ended Sep 30, 2026 was $13.01B, up 14.4% from $11.37B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.42 | $1.43 | $1.31 - $1.44 | -0.70% | Miss | +9.2% | 23 | 1 up, 1 down | Oct 21, 2026 | $13.01B |
| Jun 30, 2026 | $1.31 | $1.28 | $1.26 - $1.29 | +2.34% | Beat | +4.0% | 23 | 0 up, 1 down | Jul 16, 2026 | $12.59B |
| Mar 31, 2026 | $1.15 | $1.15 | $1.12 - $1.21 | 0.00% | In line | +5.5% | 24 | 0 up, 7 down | Apr 16, 2026 | $11.16B |
| Dec 31, 2025 | $1.50 | $1.49 | $1.45 - $1.51 | +0.67% | Beat | +11.9% | 23 | 1 up, 1 down | Jan 22, 2026 | $11.46B |
| Sep 30, 2025 | $1.30 | $1.30 | $1.28 - $1.33 | 0.00% | In line | +7.4% | 24 | 2 up, 2 down | Oct 15, 2025 | $11.37B |
| Jun 30, 2025 | $1.26 | $1.26 | $1.14 - $1.30 | 0.00% | In line | +10.5% | 22 | 1 up, 0 down | Jul 17, 2025 | $11.14B |
| Mar 31, 2025 | $1.09 | $1.07 | $1.05 - $1.09 | +1.87% | Beat | +11.2% | 20 | 3 up, 1 down | Apr 16, 2025 | $10.36B |
| Dec 31, 2024 | $1.34 | $1.34 | $1.33 - $1.37 | 0.00% | In line | +12.6% | 20 | 2 up, 1 down | Jan 22, 2025 | $10.97B |
| Sep 30, 2024 | $1.21 | $1.20 | $1.18 - $1.23 | +0.83% | Beat | +6.1% | 21 | 1 up, 1 down | Oct 16, 2024 | $10.63B |
| Jun 30, 2024 | $1.14 | $1.10 | $1.09 - $1.12 | +3.64% | Beat | +5.6% | 20 | 1 up, 2 down | Jul 18, 2024 | $10.38B |
| Mar 31, 2024 | $0.98 | $0.95 | $0.94 - $0.99 | +3.16% | Beat | -4.9% | 20 | 0 up, 1 down | Apr 17, 2024 | $9.96B |
| Dec 31, 2023 | $1.19 | $1.19 | $1.18 - $1.21 | 0.00% | In line | +15.5% | 19 | 1 up, 0 down | Jan 24, 2024 | $10.24B |
| Sep 30, 2023 | $1.14 | $1.10 | $1.06 - $1.12 | +3.64% | Beat | -0.9% | 19 | 2 up, 1 down | Oct 18, 2023 | $10.14B |
| Jun 30, 2023 | $1.08 | $1.05 | $1.01 - $1.10 | +2.86% | Beat | -24.5% | 19 | 3 up, 0 down | Jul 20, 2023 | $9.98B |
| Mar 31, 2023 | $1.03 | $0.99 | $0.96 - $1.02 | +4.04% | Beat | -40.5% | 19 | 2 up, 0 down | Apr 19, 2023 | $9.75B |
| Dec 31, 2022 | $1.03 | $0.94 | $0.87 - $1.09 | +9.57% | Beat | -22.0% | 19 | 4 up, 0 down | Jan 25, 2023 | $10.09B |
| Sep 30, 2022 | $1.15 | $0.94 | $0.84 - $1.10 | +22.34% | Beat | -17.9% | 20 | 4 up, 0 down | Oct 19, 2022 | $10.41B |
| Jun 30, 2022 | $1.43 | $1.14 | $1.00 - $1.28 | +25.44% | Beat | +22.2% | 18 | 1 up, 1 down | Jul 20, 2022 | $11.26B |
| Mar 31, 2022 | $1.73 | $1.46 | $1.32 - $1.51 | +18.49% | Beat | +31.1% | 19 | 1 up, 3 down | Apr 20, 2022 | $11.89B |
| Dec 31, 2021 | $1.32 | $1.21 | $1.14 - $1.35 | +9.09% | Beat | -9.0% | 18 | 5 up, 0 down | Jan 26, 2022 | $11.47B |
| Sep 30, 2021 | $1.40 | $0.95 | $0.90 - $1.17 | +47.37% | Beat | +42.9% | 20 | N/A | Oct 20, 2021 | $10.93B |
| Jun 30, 2021 | $1.17 | $1.02 | $0.98 - $1.07 | +14.71% | Beat | +105.3% | 20 | N/A | Jul 22, 2021 | $10.22B |
| Mar 31, 2021 | $1.32 | $1.27 | $1.11 - $1.43 | +3.94% | Beat | +103.1% | 20 | N/A | Apr 20, 2021 | $10.46B |
| Dec 31, 2020 | $1.45 | $1.35 | $1.30 - $1.40 | +7.41% | Beat | +52.6% | 19 | N/A | Jan 27, 2021 | $10.70B |
| Sep 30, 2020 | $0.98 | $0.91 | $0.84 - $0.98 | +7.69% | Beat | +16.7% | 19 | N/A | Oct 21, 2020 | $8.85B |
| Jun 30, 2020 | $0.57 | $0.42 | $0.29 - $0.53 | +35.71% | Beat | -30.5% | 18 | N/A | Jul 16, 2020 | $7.33B |
| Mar 31, 2020 | $0.65 | $0.61 | $0.17 - $0.69 | +6.56% | Beat | +3.2% | 14 | N/A | Apr 16, 2020 | $7.73B |
| Dec 31, 2019 | $0.95 | $0.95 | $0.94 - $0.95 | 0.00% | In line | +17.3% | 17 | N/A | Jan 22, 2020 | $8.31B |
| Sep 30, 2019 | $0.84 | $0.84 | $0.83 - $0.85 | 0.00% | In line | +12.0% | 18 | N/A | Oct 16, 2019 | $8.08B |
| Jun 30, 2019 | $0.82 | $0.80 | $0.78 - $0.81 | +2.50% | Beat | +12.3% | 20 | N/A | Jul 17, 2019 | $7.98B |
| Mar 31, 2019 | $0.63 | $0.62 | $0.60 - $0.63 | +1.61% | Beat | +6.8% | 20 | N/A | Apr 17, 2019 | $7.54B |
| Dec 31, 2018 | $0.81 | $0.81 | $0.80 - $0.82 | 0.00% | In line | +9.5% | 21 | N/A | Jan 23, 2019 | $7.76B |
| Sep 30, 2018 | $0.75 | $0.75 | $0.73 - $0.77 | 0.00% | In line | +13.6% | 19 | N/A | Oct 17, 2018 | $7.66B |
| Jun 30, 2018 | $0.73 | $0.71 | $0.70 - $0.72 | +2.82% | Beat | +17.7% | 18 | N/A | Jul 18, 2018 | $7.77B |
| Mar 31, 2018 | $0.59 | $0.58 | $0.57 - $0.59 | +1.72% | Beat | +22.9% | 18 | N/A | Apr 18, 2018 | $7.39B |
| Dec 31, 2017 | $0.74 | $0.73 | $0.71 - $0.76 | +1.37% | Beat | +13.8% | 18 | N/A | Jan 24, 2018 | $7.59B |
| Sep 30, 2017 | $0.66 | $0.65 | $0.64 - $0.66 | +1.54% | Beat | +11.9% | 18 | N/A | Oct 18, 2017 | $6.83B |
| Jun 30, 2017 | $0.62 | $0.61 | $0.59 - $0.62 | +1.64% | Beat | +12.7% | 18 | N/A | Jul 20, 2017 | $6.64B |
| Mar 31, 2017 | $0.48 | $0.43 | N/A | +11.63% | Beat | +17.1% | N/A | N/A | Apr 19, 2017 | $6.33B |
| Dec 31, 2016 | $0.65 | $0.65 | N/A | 0.00% | In line | +4.8% | N/A | N/A | Jan 25, 2017 | $5.33B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $5.15, up 10.3% from the year before. It was $2.20 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $5.15 | +10.3% |
| Dec 31, 2024 | $4.67 | +5.2% |
| Dec 31, 2023 | $4.44 | -16.9% |
| Dec 31, 2022 | $5.34 | +2.5% |
| Dec 31, 2021 | $5.21 | +42.7% |
| Dec 31, 2020 | $3.65 | +12.7% |
| Dec 31, 2019 | $3.24 | +12.5% |
| Dec 31, 2018 | $2.88 | +15.2% |
| Dec 31, 2017 | $2.50 | +13.6% |
| Dec 31, 2016 | $2.20 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 12,000 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 11,547 | 11 | |
| 2026Q2 | Jun 30, 2026 | 5,775 | 12 | |
| 2026Q1 | Mar 31, 2026 | 7,418 | 13 | |
| 2025Q4 | Dec 31, 2025 | 10,276 | 12 | |
| 2025Q3 | Sep 30, 2025 | 10,178 | 12 | |
| 2025Q2 | Jun 30, 2025 | 5,400 | 13 | |
| 2025Q1 | Mar 31, 2025 | 8,858 | 12 | |
| 2024Q4 | Dec 31, 2024 | 7,819 | 13 |
2026Q3 Earnings Call
Opening remarks
Mike Comilla Vice President, Investor Relations Good morning, and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer, and Phil Boudreau, Executive Vice President, Finance, and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we'll take your questions. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological, and other factors that may affect Abbott's operations are discussed in Item 1A, Risk Factors, to our annual report on Form 10-K for the year ended December 31, 2025. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. On today's conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott's ongoing business performance. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com. Note that Abbott has not provided the related GAAP financial measures on a forward-looking basis for the non-GAAP financial measures for which it is providing guidance because the company is unable to predict with reasonable certainty, and without unreasonable effort, the timing and impact of certain items which could significantly impact Abbott's results in accordance with GAAP. Unless otherwise noted, our commentary on sales growth refers to comparable sales growth. Our definition of comparable sales growth can be found on page 2 of our press release issued earlier today, and a reconciliation table containing the data needed to calculate comparable sales growth can be found on pages 16 and 17. With that, I will now turn the call over to Robert.
Robert Ford Chairman and CEO Thanks, Mike. Today marks an important milestone in Abbott's history. Along with reporting our third quarter results, we announced our intention to separate our nutrition business into an independent, publicly traded company. This decision follows a comprehensive strategic review and reflects our strong belief that both Abbott and the nutrition business can create greater value and achieve their maximum potential as independent organizations. Abbott entered the nutrition business more than 60 years ago. Since that time, we built a strong foundation anchored by a talented global organization, iconic brands, scale, and established market leadership positions across the pediatric and adult nutrition categories. The nutrition market has evolved over time, with the pace of change accelerating significantly in recent years.
Frequently Asked Questions About ABT
When is Abbott Laboratories's next earnings date?
Abbott Laboratories's next earnings report is expected for Jan 20, 2027.
Did ABT beat earnings estimates last quarter?
No. Abbott Laboratories reported EPS of $1.42 for the quarter ended Sep 30, 2026, below the $1.43 estimate by 0.70%.
What EPS do analysts expect from ABT next quarter?
The consensus EPS estimate for Abbott Laboratories for the quarter ending Dec 31, 2026 is $1.65 from 27 analysts, with estimates from $1.60 to $1.73.
How often does ABT beat earnings estimates?
Abbott Laboratories beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of +0.52%.
ABT pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts